Table 3.

Adjusted ORs and relative 95% CIs of cohort effect on pregnancy outcomes

Cohort	Abortion	Pregnancy losses	Elective termination of pregnancy
	OR (95% CI)	OR (95% CI)	OR (95% CI)
Main analysis
Women without RA (reference)—N=1690	1	1	1
RA women treated with MTX—N=223	1.76 (1.17 to 2.60) **	2.22 (1.40 to 3.45) ***	0.97 (0.50 to 1.76)
RA women not treated with MTX— N=323	1.13 (0.84 to 1.49)	1.11 (0.78 to 1.56)	1.10 (0.72 to 1.63)
First sensitivity analysis
Women without RA (reference)—N=1690	1	1	1
RA women treated with MTX—N=190	1.56 (1.01 to 2.38) *	1.98 (1.20 to 3.18) **	0.91 (0.44 to 1.72)
RA women not treated with MTX—N=304	1.17 (0.87 to 1.56)	1.13 (0.78 to 1.59)	1.17 (0.77 to 1.74)
Second sensitivity analysis
Women without RA (reference)—N=1499	1	1	1
RA women treated with MTX—N=189	1.97 (1.27 to 3.01) **	2.37 (1.45 to 3.82) ***	1.08 (0.52 to 2.07)
RA women not treated with MTX—N=288	1.08 (0.79 to 1.47)	0.89 (0.59 to 1.30)	1.36 (0.88 to 2.04)

Adjustment for age, diabetes, hypertension, thyroid diseases, chronic kidney failure and glucocorticoids use.

Main analysis, first sensitivity analysis (excluding patients with cotreatment with sulfasalazine or leflunomide) and second sensitivity analysis (excluding patients treated with oral contraceptive).

*p<0.05, **p<0.01, ***p<0.001.

MTX, methotrexate; RA, rheumatoid arthritis.